| Year |
Citation |
Score |
| 2015 |
Asiimwe-Kateera B, Veldhuijzen N, Balinda JP, Rusine J, Eagle S, Vyankandondera J, Mugabekazi J, Ondoa P, Boer K, Asiimwe A, Lange J, Reiss P, van de Wijgert J. Combination Antiretroviral Therapy for HIV in Rwandan Adults: Clinical Outcomes and Impact on Reproductive Health up to 24 Months. Aids Research and Treatment. 2015: 740212. PMID 26257954 DOI: 10.1155/2015/740212 |
0.484 |
|
| 2014 |
Hull M, Lange J, Montaner JS. Treatment as prevention--where next? Current Hiv/Aids Reports. 11: 496-504. PMID 25384357 DOI: 10.1007/S11904-014-0237-5 |
0.509 |
|
| 2014 |
Mutwa PR, Boer KR, Asiimwe-Kateera B, Tuyishimire D, Muganga N, Lange JM, van de Wijgert J, Asiimwe A, Reiss P, Geelen SP. Safety and effectiveness of combination antiretroviral therapy during the first year of treatment in HIV-1 infected Rwandan children: a prospective study. Plos One. 9: e111948. PMID 25365302 DOI: 10.1371/journal.pone.0111948 |
0.337 |
|
| 2014 |
Grubb IR, Beckham SW, Kazatchkine M, Thomas RM, Albers ER, Cabral M, Lange J, Vella S, Kurian M, Beyrer C. Maximizing the benefits of antiretroviral therapy for key affected populations. Journal of the International Aids Society. 17: 19320. PMID 25043380 DOI: 10.7448/Ias.17.1.19320 |
0.529 |
|
| 2014 |
Sigaloff KC, Lange JM, Montaner J. Global response to HIV: treatment as prevention, or treatment for treatment? Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 59: S7-S11. PMID 24926037 DOI: 10.1093/cid/ciu267 |
0.327 |
|
| 2014 |
Grijsen ML, Wit FW, Jurriaans S, Kroon FP, Schippers EF, Koopmans P, Gras L, Lange JM, Prins JM. Temporary treatment during primary HIV infection does not affect virologic response to subsequent long-term treatment. Plos One. 9: e89639. PMID 24699072 DOI: 10.1371/journal.pone.0089639 |
0.344 |
|
| 2014 |
Landolt NK, Phanuphak N, Ubolyam S, Pinyakorn S, Kerr S, Ahluwalia J, Thongpaeng P, Thammajaruk N, Cremers S, Thomas T, Chaithongwongwatthana S, Lange JM, Ananworanich J. Significant decrease of ethinylestradiol with nevirapine, and of etonogestrel with efavirenz in HIV-positive women. Journal of Acquired Immune Deficiency Syndromes (1999). 66: e50-2. PMID 24608892 DOI: 10.1097/QAI.0000000000000134 |
0.421 |
|
| 2014 |
Mutwa PR, Boer KR, Rusine J, Muganga N, Tuyishimire D, Schuurman R, Reiss P, Lange JM, Geelen SP. Long-term effectiveness of combination antiretroviral therapy and prevalence of HIV drug resistance in HIV-1-infected children and adolescents in Rwanda. The Pediatric Infectious Disease Journal. 33: 63-9. PMID 24352189 DOI: 10.1097/INF.0b013e31829e6b9f |
0.332 |
|
| 2014 |
Lange J. Implementation of TasP: challenges and opportunities Bmc Infectious Diseases. 14: 1-1. DOI: 10.1186/1471-2334-14-S2-S8 |
0.54 |
|
| 2013 |
Avihingsanon A, Kerr SJ, Punyawudho B, van der Lugt J, Gorowara M, Ananworanich J, Lange JM, Cooper DA, Phanuphak P, Burger DM, Ruxrungtham K. Short communication: Aging not gender is associated with high atazanavir plasma concentrations in Asian HIV-infected patients. Aids Research and Human Retroviruses. 29: 1541-6. PMID 24088045 DOI: 10.1089/aid.2013.0069 |
0.305 |
|
| 2013 |
Nosyk B, Audoin B, Beyrer C, Cahn P, Granich R, Havlir D, Katabira E, Lange J, Lima VD, Patterson T, Strathdee SA, Williams B, Montaner J. Examining the evidence on the causal effect of HAART on transmission of HIV using the Bradford Hill criteria. Aids (London, England). 27: 1159-65. PMID 23902921 DOI: 10.1097/Qad.0B013E32835F1D68 |
0.567 |
|
| 2013 |
Baan E, de Ronde A, Stax M, Sanders RW, Luchters S, Vyankandondera J, Lange JM, Pollakis G, Paxton WA. HIV-1 autologous antibody neutralization associates with mother to child transmission. Plos One. 8: e69274. PMID 23874931 DOI: 10.1371/journal.pone.0069274 |
0.417 |
|
| 2013 |
Gomez GB, Venter WD, Lange JM, Rees H, Hankins C. North-South Corridor Demonstration Project: Ethical and Logistical Challenges in the Design of a Demonstration Study of Early Antiretroviral Treatment for Long Distance Truck Drivers along a Transport Corridor through South Africa, Zimbabwe, and Zambia. Advances in Preventive Medicine. 2013: 190190. PMID 23606977 DOI: 10.1155/2013/190190 |
0.395 |
|
| 2013 |
Cahn P, Ruxrungtham K, Gazzard B, Diaz RS, Gori A, Kotler DP, Vriesema A, Georgiou NA, Garssen J, Clerici M, Lange JM. The immunomodulatory nutritional intervention NR100157 reduced CD4+ T-cell decline and immune activation: a 1-year multicenter randomized controlled double-blind trial in HIV-infected persons not receiving antiretroviral therapy (The BITE Study). Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 57: 139-46. PMID 23511299 DOI: 10.1093/cid/cit171 |
0.48 |
|
| 2013 |
Landolt NK, Phanuphak N, Ubolyam S, Pinyakorn S, Kriengsinyot R, Ahluwalia J, Thongpaeng P, Gorowara M, Thammajaruk N, Chaithongwongwatthana S, Lange JM, Ananworanich J. Efavirenz, in contrast to nevirapine, is associated with unfavorable progesterone and antiretroviral levels when coadministered with combined oral contraceptives. Journal of Acquired Immune Deficiency Syndromes (1999). 62: 534-9. PMID 23187949 DOI: 10.1097/QAI.0b013e31827e8f98 |
0.329 |
|
| 2013 |
Mutwa PR, Boer KR, Rusine JB, Muganga N, Tuyishimire D, Reiss P, Lange JM, Geelen SP. Hepatitis B virus prevalence and vaccine response in HIV-infected children and adolescents on combination antiretroviral therapy in Kigali, Rwanda. The Pediatric Infectious Disease Journal. 32: 246-51. PMID 22976050 DOI: 10.1097/INF.0b013e318271b93d |
0.312 |
|
| 2013 |
Ramautarsing RA, van der Lugt J, Gorowara M, Sophonphan J, Ananworanich J, Lange JM, Burger DM, Phanuphak P, Ruxthungtham K, Avihingsanon A. Pharmacokinetics and 48-week safety and efficacy of generic lopinavir/ritonavir in Thai HIV-infected patients. Antiviral Therapy. 18: 249-52. PMID 22908131 DOI: 10.3851/IMP2324 |
0.425 |
|
| 2012 |
Harari A, Rozot V, Cavassini M, Bellutti Enders F, Vigano S, Tapia G, Castro E, Burnet S, Lange J, Moog C, Garin D, Costagliola D, Autran B, Pantaleo G, Bart PA. NYVAC immunization induces polyfunctional HIV-specific T-cell responses in chronically-infected, ART-treated HIV patients. European Journal of Immunology. 42: 3038-48. PMID 22930439 DOI: 10.1002/Eji.201242696 |
0.526 |
|
| 2012 |
Hermans S, Nasuuna E, van Leth F, Byhoff E, Schwarz M, Hoepelman A, Lange J, Manabe YC. Implementation and effect of intensified case finding on diagnosis of tuberculosis in a large urban HIV clinic in Uganda: a retrospective cohort study. Bmc Public Health. 12: 674. PMID 22905704 DOI: 10.1186/1471-2458-12-674 |
0.35 |
|
| 2012 |
Hamers RL, Kityo C, Lange JM, de Wit TF, Mugyenyi P. Global threat from drug resistant HIV in sub-Saharan Africa. Bmj (Clinical Research Ed.). 344: e4159. PMID 22709963 DOI: 10.1136/bmj.e4159 |
0.369 |
|
| 2012 |
Grijsen ML, Steingrover R, Wit FW, Jurriaans S, Verbon A, Brinkman K, van der Ende ME, Soetekouw R, de Wolf F, Lange JM, Schuitemaker H, Prins JM. No treatment versus 24 or 60 weeks of antiretroviral treatment during primary HIV infection: the randomized Primo-SHM trial. Plos Medicine. 9: e1001196. PMID 22479156 DOI: 10.1371/journal.pmed.1001196 |
0.453 |
|
| 2012 |
Hermans SM, Castelnuovo B, Katabira C, Mbidde P, Lange JM, Hoepelman AI, Coutinho A, Manabe YC. Integration of HIV and TB services results in improved TB treatment outcomes and earlier prioritized ART initiation in a large urban HIV clinic in Uganda. Journal of Acquired Immune Deficiency Syndromes (1999). 60: e29-35. PMID 22395671 DOI: 10.1097/QAI.0b013e318251aeb4 |
0.445 |
|
| 2012 |
Hermans SM, van Leth F, Manabe YC, Hoepelman AIM, Lange JMA, Kambugu A. Earlier initiation of antiretroviral therapy, increased tuberculosis case finding and reduced mortality in a setting of improved HIV care: A retrospective cohort study Hiv Medicine. 13: 337-344. PMID 22296211 DOI: 10.1111/j.1468-1293.2011.00980.x |
0.375 |
|
| 2012 |
Baan E, de Ronde A, Luchters S, Vyankandondera J, Lange JM, Pollakis G, Paxton WA. HIV type 1 mother-to-child transmission facilitated by distinctive glycosylation sites in the gp120 envelope glycoprotein. Aids Research and Human Retroviruses. 28: 715-24. PMID 21916748 DOI: 10.1089/AID.2011.0023 |
0.34 |
|
| 2012 |
Steingrover R, Bekker V, Beld M, Lange J, Wolthers K, Kuijpers T, Prins J. Dynamics of Epstein-Barr Virus DNA concentrations in whole blood of HIV-1-infected patients during primary HIV-1 infection Journal of the International Aids Society. 15. DOI: 10.7448/Ias.15.6.18406 |
0.566 |
|
| 2012 |
Volberding P, Greene W, Lange JMA, Gallant JE, Sewankambo N. Sande's HIV/AIDS Medicine: Medical Management of AIDS 2013: Second Edition Sande's Hiv/Aids Medicine: Medical Management of Aids 2013: Second Edition. 1-580. DOI: 10.1016/B978-1-4557-0695-2.00048-1 |
0.375 |
|
| 2011 |
Bunupuradah T, Ananworanich J, Pancharoen C, Petoumenos K, Prasitsuebsai W, Wongngam W, Ubolyam S, Sriheara C, Lange J, Phanuphak P, Puthanakit T. Randomized study of intradermal compared to intramuscular hepatitis B vaccination in HIV-infected children without severe immunosuppression. Vaccine. 29: 2962-7. PMID 21329776 DOI: 10.1016/J.Vaccine.2011.01.114 |
0.431 |
|
| 2010 |
Schellens IM, Pogany K, Westerlaken GH, Borghans JA, Miedema F, van Valkengoed IG, Kroon FP, Lange JM, Brinkman K, Prins JM, van Baarle D. Immunological analysis of treatment interruption after early highly active antiretroviral therapy. Viral Immunology. 23: 609-18. PMID 21142446 DOI: 10.1089/vim.2010.0062 |
0.342 |
|
| 2010 |
Avihingsanon A, Lewin SR, Kerr S, Chang JJ, Piyawat K, Napissanant N, Matthews GV, Dore GJ, Bowden S, Lange J, Ruxrungtham K. Efficacy of tenofovir disoproxil fumarate/emtricitabine compared with emtricitabine alone in antiretroviral-naive HIV-HBV coinfection in Thailand. Antiviral Therapy. 15: 917-22. PMID 20834105 DOI: 10.3851/Imp1645 |
0.507 |
|
| 2010 |
Zhang S, van Sighem A, Gras L, Reiss P, Smit C, Kroon F, Jurriaans S, Prins J, Lange J, de Wolf F. Clinical significance of transient HIV type-1 viraemia and treatment interruptions during suppressive antiretroviral treatment. Antiviral Therapy. 15: 555-62. PMID 20587848 DOI: 10.3851/Imp1564 |
0.513 |
|
| 2010 |
Yazdanpanah Y, Lange J, Gerstoft J, Cairns G. Earlier testing for HIV--how do we prevent late presentation? Antiviral Therapy. 15: 17-24. PMID 20442457 DOI: 10.3851/Imp1526 |
0.531 |
|
| 2010 |
Van der Borght SF, Schim van der Loeff MF, Clevenbergh P, Kabarega JP, Kamo E, van Cranenburgh K, Rijckborst H, Lange JM, Rinke de Wit TF. Long-term voluntary counseling and testing (VCT) uptake dynamics in a multicountry HIV workplace program in sub-Saharan Africa. Aids Care. 22: 195-205. PMID 20390498 DOI: 10.1080/09540120903111486 |
0.468 |
|
| 2010 |
Steingrover R, Garcia EF, van Valkengoed IG, Bekker V, Bezemer D, Kroon FP, Dekker L, Prins M, de Wolf F, Lange JM, Prins JM. Transient lowering of the viral set point after temporary antiretroviral therapy of primary HIV type 1 infection. Aids Research and Human Retroviruses. 26: 379-87. PMID 20377419 DOI: 10.1089/aid.2009.0041 |
0.4 |
|
| 2009 |
van der Lugt J, Lange J, Avihingsanon A, Ananworanich J, Sealoo S, Burger D, Gorowara M, Phanuphak P, Ruxrungtham K. Plasma concentrations of generic lopinavir/ritonavir in HIV type-1-infected individuals. Antiviral Therapy. 14: 1001-4. PMID 19918104 DOI: 10.3851/Imp1410 |
0.475 |
|
| 2009 |
Gras L, Jurriaans S, Bakker M, van Sighem A, Bezemer D, Fraser C, Lange J, Prins JM, Berkhout B, de Wolf F. Viral load levels measured at set-point have risen over the last decade of the HIV epidemic in the Netherlands. Plos One. 4: e7365. PMID 19809510 DOI: 10.1371/Journal.Pone.0007365 |
0.552 |
|
| 2009 |
Wang D, Larder B, Revell A, Montaner J, Harrigan R, De Wolf F, Lange J, Wegner S, Ruiz L, Pérez-ElÃas MJ, Emery S, Gatell J, D'Arminio Monforte A, Torti C, Zazzi M, et al. A comparison of three computational modelling methods for the prediction of virological response to combination HIV therapy. Artificial Intelligence in Medicine. 47: 63-74. PMID 19524413 DOI: 10.1016/J.Artmed.2009.05.002 |
0.472 |
|
| 2009 |
van der Lugt J, Gorowara M, Avihingsanon A, Burger D, Ananworanich J, Sringam K, Kerr S, Wit F, Lange J, Ruxrungtham K. Reducing the boosting dose of ritonavir does not affect saquinavir plasma concentrations in HIV-1-infected individuals. Aids (London, England). 23: 1176-9. PMID 19451794 DOI: 10.1097/Qad.0B013E32832B4461 |
0.447 |
|
| 2009 |
Van der Borght SF, Clevenbergh P, Rijckborst H, Nsalou P, Onyia N, Lange JM, de Wit TF, Van der Loeff MF. Mortality and morbidity among HIV type-1-infected patients during the first 5 years of a multicountry HIV workplace programme in Africa. Antiviral Therapy. 14: 63-74. PMID 19320238 |
0.48 |
|
| 2009 |
Naarding M, Luchters S, Vyankandondera J, Wit F, Veldhuijzen N, Kankindi B, Sparidans R, Beijnen J, Pollakis G, Boelaert J, Lange J, Paxton W. Use of chloroquine in reducing mother to child transmission of HIV-1 during breastfeeding Retrovirology. 6: O13. DOI: 10.1186/1742-4690-6-S1-O13 |
0.531 |
|
| 2009 |
Lange JMA. Antiretroviral treatment and care of HIV The Hiv Pandemic: Local and Global Implications. DOI: 10.1093/acprof:oso/9780199237401.003.0006 |
0.423 |
|
| 2009 |
Phanuphak P, Lange J, Cooper D. HIV in Asia: The way forward Asian Biomedicine. 3: 3-7. |
0.497 |
|
| 2008 |
Ananworanich J, Kosalaraksa P, Siangphoe U, Engchanil C, Pancharoen C, Lumbiganon P, Intasan J, Apateerapong W, Chuenyam T, Ubolyam S, Bunupuradah T, Lange J, Cooper DA, Phanuphak P. A feasibility study of immediate versus deferred antiretroviral therapy in children with HIV infection. Aids Research and Therapy. 5: 24. PMID 18957095 DOI: 10.1186/1742-6405-5-24 |
0.441 |
|
| 2008 |
Steingrover R, Pogány K, Fernandez Garcia E, Jurriaans S, Brinkman K, Schuitemaker H, Miedema F, Lange JM, Prins JM. HIV-1 viral rebound dynamics after a single treatment interruption depends on time of initiation of highly active antiretroviral therapy. Aids (London, England). 22: 1583-8. PMID 18670217 DOI: 10.1097/QAD.0b013e328305bd77 |
0.481 |
|
| 2008 |
Grant RM, Hamer D, Hope T, Johnston R, Lange J, Lederman MM, Lieberman J, Miller CJ, Moore JP, Mosier DE, Richman DD, Schooley RT, Springer MS, Veazey RS, Wainberg MA. Whither or wither microbicides? Science (New York, N.Y.). 321: 532-4. PMID 18653884 DOI: 10.1126/Science.1160355 |
0.358 |
|
| 2008 |
Smit C, Hallett TB, Lange J, Garnett G, de Wolf F. Late entry to HIV care limits the impact of anti-retroviral therapy in The Netherlands. Plos One. 3: e1949. PMID 18398473 DOI: 10.1371/Journal.Pone.0001949 |
0.534 |
|
| 2008 |
Cohen MS, Hellmann N, Levy JA, DeCock K, Lange J. The spread, treatment, and prevention of HIV-1: evolution of a global pandemic. The Journal of Clinical Investigation. 118: 1244-54. PMID 18382737 DOI: 10.1172/Jci34706 |
0.564 |
|
| 2008 |
van der Lugt J, Autar RS, Ubolyam S, Garcia EF, Sankote J, Avihingsanon A, Avihingson A, Chuenyam T, Cooper DA, Lange J, Phanuphak P, Wit F, Ruxrungtham K, Burger D. Pharmacokinetics and short-term efficacy of a double-boosted protease inhibitor regimen in treatment-naive HIV-1-infected adults. The Journal of Antimicrobial Chemotherapy. 61: 1145-53. PMID 18285316 DOI: 10.1093/Jac/Dkn050 |
0.523 |
|
| 2008 |
Wit FWNM, Lange JMA, Volberding PA. New HIV Drug Development Global Hiv/Aids Medicine. 123-134. DOI: 10.1016/B978-1-4160-2882-6.50016-2 |
0.412 |
|
| 2008 |
Volberding PA, Sande MA, Greene WC, Lange JMA. Global HIV/AIDS Medicine Global Hiv/Aids Medicine. |
0.485 |
|
| 2007 |
Autar RS, Boyd MA, Wit FW, Ruxrungthams K, Sankote J, Lange J, Cooper DA, Phanuphak P, Burger DM, Reiss P. Relationships between drug exposure, changes in metabolic parameters and body fat in HIV-infected patients switched to a nucleoside sparing regimen. Antiviral Therapy. 12: 1265-71. PMID 18240866 |
0.401 |
|
| 2007 |
Vermeulen JN, Prins JM, Bunnik E, Hack CE, Jurriaans S, Miedema F, Lange JM, Schuitemaker H. Intravenous immunoglobulin (IVIG) treatment for modulation of immune activation in human immunodeficiency virus type 1 infected therapy-naive individuals. Aids Research and Human Retroviruses. 23: 1348-53. PMID 18184076 DOI: 10.1089/aid.2006.0210 |
0.32 |
|
| 2007 |
Reynes J, Arastéh K, Clotet B, Cohen C, Cooper DA, Delfraissy JF, Eron JJ, Henry K, Katlama C, Kuritzkes DR, Lalezari JP, Lange J, Lazzarin A, Montaner JS, Nelson M, et al. TORO: ninety-six-week virologic and immunologic response and safety evaluation of enfuvirtide with an optimized background of antiretrovirals. Aids Patient Care and Stds. 21: 533-43. PMID 17711378 DOI: 10.1089/Apc.2006.0174 |
0.438 |
|
| 2007 |
Autar RS, Wit FW, Sankote J, Sutthichom D, Kimenai E, Hassink E, Hill A, Cooper DA, Phanuphak P, Lange JM, Burger DM, Ruxrungtham K. Ketoconazole is inferior to ritonavir as an alternative booster for saquinavir in a once daily regimen in Thai HIV-1 infected patients. Aids (London, England). 21: 1535-9. PMID 17630547 DOI: 10.1097/QAD.0b013e3280da8ba8 |
0.339 |
|
| 2007 |
Nelson MR, Katlama C, Montaner JS, Cooper DA, Gazzard B, Clotet B, Lazzarin A, Schewe K, Lange J, Wyatt C, Curtis S, Chen SS, Smith S, Bischofberger N, Rooney JF. The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years. Aids (London, England). 21: 1273-81. PMID 17545703 DOI: 10.1097/Qad.0B013E3280B07B33 |
0.499 |
|
| 2007 |
Sankatsing RR, Wit FW, Pakker N, Vyankandondera J, Mmiro F, Okong P, Kastelein JJ, Lange JM, Stroes ES, Reiss P. Effects of nevirapine, compared with lamivudine, on lipids and lipoproteins in HIV-1-uninfected newborns: the stopping infection from mother-to-child via breast-feeding in Africa lipid substudy. The Journal of Infectious Diseases. 196: 15-22. PMID 17538878 DOI: 10.1086/518248 |
0.369 |
|
| 2007 |
Larder B, Wang D, Revell A, Montaner J, Harrigan R, De Wolf F, Lange J, Wegner S, Ruiz L, Pérez-ElÃas MJ, Emery S, Gatell J, Monforte AD, Torti C, Zazzi M, et al. The development of artificial neural networks to predict virological response to combination HIV therapy. Antiviral Therapy. 12: 15-24. PMID 17503743 |
0.335 |
|
| 2007 |
Vermeulen JN, Meijer DK, Over J, Lange J, Proost JH, Bakker HI, Beljaars L, Wit FW, Prins JM. A phase I/IIa study with succinylated human serum albumin (Suc-HSA), a candidate HIV-1 fusion inhibitor. Antiviral Therapy. 12: 273-8. PMID 17503670 |
0.455 |
|
| 2007 |
Scherpbier HJ, Bekker V, Pajkrt D, Jurriaans S, Lange JM, Kuijpers TW. Once-daily highly active antiretroviral therapy for HIV-infected children: safety and efficacy of an efavirenz-containing regimen. Pediatrics. 119: e705-15. PMID 17308244 DOI: 10.1542/peds.2006-1367 |
0.401 |
|
| 2007 |
Sankatsing SU, Cornelissen M, Kloosterboer N, Crommentuyn KM, Bosch TM, Mul FP, Jurriaans S, Huitema AD, Beijnen JH, Lange JM, Prins JM, Schuitemaker H. Antiviral activity of HIV type 1 protease inhibitors nelfinavir and indinavir in vivo is not influenced by P-glycoprotein activity on CD4+ T cells. Aids Research and Human Retroviruses. 23: 19-27. PMID 17263628 DOI: 10.1089/Aid.2006.0027 |
0.395 |
|
| 2007 |
Sow PS, Otieno LF, Bissagnene E, Kityo C, Bennink R, Clevenbergh P, Wit FW, Waalberg E, Rinke de Wit TF, Lange JM. Implementation of an antiretroviral access program for HIV-1-infected individuals in resource-limited settings: clinical results from 4 African countries. Journal of Acquired Immune Deficiency Syndromes (1999). 44: 262-7. PMID 17146376 DOI: 10.1097/QAI.0b013e31802bf109 |
0.456 |
|
| 2006 |
Koekkoek S, Eggermont L, De Sonneville L, Jupimai T, Wicharuk S, Apateerapong W, Chuenyam T, Lange J, Wit F, Pancharoen C, Phanuphak P, Ananworanich J. Effects of highly active antiretroviral therapy (HAART) on psychomotor performance in children with HIV disease. Journal of Neurology. 253: 1615-24. PMID 17093898 DOI: 10.1007/S00415-006-0277-X |
0.519 |
|
| 2006 |
Derdelinckx I, Wainberg MA, Lange JM, Hill A, Halima Y, Boucher CA. Criteria for drugs used in pre-exposure prophylaxis trials against HIV infection. Plos Medicine. 3: e454. PMID 17090213 DOI: 10.1371/Journal.Pmed.0030454 |
0.492 |
|
| 2006 |
Bekker V, Scherpbier H, Beld M, Piriou E, van Breda A, Lange J, van Leth F, Jurriaans S, Alders S, Wertheim-van Dillen P, van Baarle D, Kuijpers T. Epstein-Barr virus infects B and non-B lymphocytes in HIV-1-infected children and adolescents. The Journal of Infectious Diseases. 194: 1323-30. PMID 17041860 DOI: 10.1086/508197 |
0.494 |
|
| 2006 |
Boyd MA, Dixit NM, Siangphoe U, Buss NE, Salgo MP, Lange JM, Phanuphak P, Cooper DA, Perelson AS, Ruxrungtham K. Viral decay dynamics in HIV-infected patients receiving ritonavir-boosted saquinavir and efavirenz with or without enfuvirtide: a randomized, controlled trial (HIV-NAT 012). The Journal of Infectious Diseases. 194: 1319-22. PMID 17041859 DOI: 10.1086/508291 |
0.461 |
|
| 2006 |
Van der Borght S, Rinke de Wit TF, Janssens V, Schim van der Loeff MF, Rijckborst H, Lange JM. HAART for the HIV-infected employees of large companies in Africa. Lancet (London, England). 368: 547-50. PMID 16890844 DOI: 10.1016/S0140-6736(06)69165-4 |
0.468 |
|
| 2006 |
Boyd MA, Srasuebkul P, Khongphattanayothin M, Ruxrungtham K, Hassink EA, Duncombe CJ, Ubolyam S, Burger DM, Reiss P, Stek M, Lange J, Cooper DA, Phanuphak P. Boosted versus unboosted indinavir with zidovudine and lamivudine in nucleoside pre-treated patients: a randomized, open-label trial with 112 weeks of follow-up (HIV-NAT 005). Antiviral Therapy. 11: 223-32. PMID 16640103 |
0.446 |
|
| 2006 |
Boyd MA, Srasuebkul P, Ruxrungtham K, Mackenzie PI, Uchaipichat V, Stek M, Lange JM, Phanuphak P, Cooper DA, Udomuksorn W, Miners JO. Relationship between hyperbilirubinaemia and UDP-glucuronosyltransferase 1A1 (UGT1A1) polymorphism in adult HIV-infected Thai patients treated with indinavir. Pharmacogenetics and Genomics. 16: 321-9. PMID 16609363 DOI: 10.1097/01.fpc.0000197465.14340.d4 |
0.307 |
|
| 2006 |
Jansen CA, Piriou E, De Cuyper IM, van Dort K, Lange JM, Miedema F, van Baarle D. Long-term highly active antiretroviral therapy in chronic HIV-1 infection: evidence for reconstitution of antiviral immunity. Antiviral Therapy. 11: 105-16. PMID 16518966 |
0.39 |
|
| 2006 |
Bekker V, Scherpbier HJ, Steingrover R, Jurriaans S, Lange JM, Wolthers KC, Kuijpers TW. Viral dynamics after starting first-line HAART in HIV-1-infected children. Aids (London, England). 20: 517-23. PMID 16470115 DOI: 10.1097/01.aids.0000210605.86009.5e |
0.395 |
|
| 2006 |
Ananworanich J, Chantaphakul H, Teeratakulpisarn S, Siangphoe U, Ubolyam S, Chuenyam T, Ungsedhaphan C, Lange J, Cooper D, Phanuphak P, Ruxrungtham K. No effect of interleukin-2 on IgE levels given in addition to antiretroviral therapy in HIV-infected adults with CD4 >300 cells/mm3. Asian Pacific Journal of Allergy and Immunology. 23: 23-8. PMID 15997871 |
0.346 |
|
| 2006 |
Jansen CA, De Cuyper IM, Steingrover R, Jurriaans S, Sankatsing SU, Prins JM, Lange JM, van Baarle D, Miedema F. Analysis of the effect of highly active antiretroviral therapy during acute HIV-1 infection on HIV-specific CD4 T cell functions. Aids (London, England). 19: 1145-54. PMID 15990567 DOI: 10.1097/01.aids.0000176214.17990.94 |
0.488 |
|
| 2006 |
Kerr SJ, Lange J, Cooper DA, Phanupak P, Ruxrungtham K. HIV-NAT Promoting Rational and Evidence-based Use of Antiretroviral Therapies Asia-Pacific Biotech News. 10: 1229-1234. DOI: 10.1142/S0219030306001820 |
0.527 |
|
| 2005 |
Autar RS, Wit FW, Sankote J, Mahanontharit A, Anekthananon T, Mootsikapun P, Sujaikaew K, Cooper DA, Lange JM, Phanuphak P, Ruxrungtham K, Burger DM. Nevirapine plasma concentrations and concomitant use of rifampin in patients coinfected with HIV-1 and tuberculosis. Antiviral Therapy. 10: 937-43. PMID 16430199 |
0.378 |
|
| 2005 |
Vrisekoop N, Sankatsing SU, Jansen CA, Roos MT, Otto SA, Schuitemaker H, Lange JM, Prins JM, Miedema F. Short communication: No detrimental immunological effects of mycophenolate mofetil and HAART in treatment-naive acute and chronic HIV-1-infected patients. Aids Research and Human Retroviruses. 21: 991-6. PMID 16379601 DOI: 10.1089/aid.2005.21.991 |
0.386 |
|
| 2005 |
Trottier B, Walmsley S, Reynes J, Piliero P, O'Hearn M, Nelson M, Montaner J, Lazzarin A, Lalezari J, Katlama C, Henry K, Cooper D, Clotet B, Arastéh K, Delfraissy JF, ... ... Lange J, et al. Safety of enfuvirtide in combination with an optimized background of antiretrovirals in treatment-experienced HIV-1-infected adults over 48 weeks. Journal of Acquired Immune Deficiency Syndromes (1999). 40: 413-21. PMID 16280695 DOI: 10.1097/01.Qai.0000185313.48933.2C |
0.375 |
|
| 2005 |
Nelson M, Arastéh K, Clotet B, Cooper DA, Henry K, Katlama C, Lalezari JP, Lazzarin A, Montaner JS, O'Hearn M, Piliero PJ, Reynes J, Trottier B, Walmsley SL, Cohen C, ... ... Lange J, et al. Durable efficacy of enfuvirtide over 48 weeks in heavily treatment-experienced HIV-1-infected patients in the T-20 versus optimized background regimen only 1 and 2 clinical trials. Journal of Acquired Immune Deficiency Syndromes (1999). 40: 404-12. PMID 16280694 DOI: 10.1097/01.Qai.0000185314.56556.C3 |
0.459 |
|
| 2005 |
Piriou E, Jansen CA, van Dort K, De Cuyper I, Nanlohy NM, Lange JM, van Oers MH, Miedema F, van Baarle D. Reconstitution of EBV latent but not lytic antigen-specific CD4+ and CD8+ T cells after HIV treatment with highly active antiretroviral therapy. Journal of Immunology (Baltimore, Md. : 1950). 175: 2010-7. PMID 16034146 DOI: 10.4049/jimmunol.175.3.2010 |
0.393 |
|
| 2005 |
Lange JM. We must not let protestors derail trials of pre-exposure prophylaxis for HIV. Plos Medicine. 2: e248. PMID 16008501 DOI: 10.1371/journal.pmed.0020248 |
0.408 |
|
| 2005 |
Bekker V, Bronke C, Scherpbier HJ, Weel JF, Jurriaans S, Wertheim-van Dillen PM, van Leth F, Lange JM, Tesselaar K, van Baarle D, Kuijpers TW. Cytomegalovirus rather than HIV triggers the outgrowth of effector CD8+CD45RA+CD27- T cells in HIV-1-infected children. Aids (London, England). 19: 1025-34. PMID 15958833 DOI: 10.1097/01.aids.0000174448.25132.ad |
0.47 |
|
| 2005 |
Boyd M, Mootsikapun P, Burger D, Chuenyam T, Ubolyam S, Mahanontharit A, Sangkote J, Bunyaprawit P, Horsakulchai M, Lange J, Cooper D, Phanuphak P, Ruxrungtham K. Pharmacokinetics of reduced-dose indinavir/ritonavir 400/100 mg twice daily in HIV-1-infected Thai patients. Antiviral Therapy. 10: 301-7. PMID 15865224 |
0.341 |
|
| 2005 |
van Leth F, Huisamen CB, Badaro R, Vandercam B, de Wet J, Montaner JS, Hall DB, Wit FW, Lange JM. Plasma HIV-1 RNA decline within the first two weeks of treatment is comparable for nevirapine, efavirenz, or both drugs combined and is not predictive of long-term virologic efficacy: A 2NN substudy. Journal of Acquired Immune Deficiency Syndromes (1999). 38: 296-300. PMID 15735447 |
0.361 |
|
| 2005 |
Nuesch R, Ananworanich J, Sirivichayakul S, Ubolyam S, Siangphoe U, Hill A, Cooper D, Lange J, Phanuphak P, Ruxrungtham K. Development of HIV with drug resistance after CD4 cell count-guided structured treatment interruptions in patients treated with highly active antiretroviral therapy after dual-nucleoside analogue treatment. Clinical Infectious Diseases. 40: 728-734. PMID 15714420 DOI: 10.1086/427878 |
0.504 |
|
| 2005 |
Cardiello PG, Hassink E, Ananworanich J, Srasuebkul P, Samor T, Mahanontharit A, Ruxrungtham K, Hirschel B, Lange J, Phanuphak P, Cooper DA. A prospective, randomized trial of structured treatment interruption for patients with chronic HIV type 1 infection Clinical Infectious Diseases. 40: 594-600. PMID 15712083 DOI: 10.1086/427695 |
0.398 |
|
| 2005 |
Van der Bij AK, Kloosterboer N, Prins M, Boeser-Nunnink B, Geskus RB, Lange JM, Coutinho RA, Schuitemaker H. GB virus C coinfection and HIV-1 disease progression: The Amsterdam Cohort Study. The Journal of Infectious Diseases. 191: 678-85. PMID 15688280 DOI: 10.1086/427559 |
0.447 |
|
| 2005 |
Ananworanich J, Moor Z, Siangphoe U, Chan J, Cardiello P, Duncombe C, Phanuphak P, Ruxrungtham K, Lange J, Cooper DA. Incidence and risk factors for rash in Thai patients randomized to regimens with nevirapine, efavirenz or both drugs. Aids. 19: 185-192. PMID 15668544 DOI: 10.1097/00002030-200501280-00011 |
0.41 |
|
| 2005 |
Duncombe C, Kerr SJ, Ruxrungtham K, Dore GJ, Law MG, Emery S, Lange JM, Phanuphak P, Cooper DA. HIV disease progression in a patient cohort treated via a clinical research network in a resource limited setting. Aids (London, England). 19: 169-78. PMID 15668542 DOI: 10.1097/00002030-200501280-00009 |
0.374 |
|
| 2005 |
Safreed-Harmon K, Cooper DA, Lange JM, Duncombe C, Phanuphak P. The HIV Netherlands Australia Thailand research collaboration: lessons from 7 years of clinical research. Aids (London, England). 18: 1971-8. PMID 15577618 DOI: 10.1097/00002030-200410210-00001 |
0.334 |
|
| 2005 |
Ungsedhapand C, Srasuebkul P, Cardiello P, Ruxrungtham K, Ratanasuwan W, Kroon ED, Tongtalung M, Juengprasert N, Ubolyam S, Siangphoe U, Emery S, Lange JM, Cooper DA, Phanuphak P. Three-year durability of dual-nucleoside versus triple-nucleoside therapy in a Thai population with HIV infection. Journal of Acquired Immune Deficiency Syndromes (1999). 36: 693-701. PMID 15167288 DOI: 10.1097/00126334-200406010-00006 |
0.424 |
|
| 2004 |
Wainberg MA, Lange JM, Gayle HD, McClure C, Sterritt C. eJIAS: The Journal of HIV/AIDS Science and Medicine in the Developing World. Journal of the International Aids Society. 6: 56. PMID 19825121 DOI: 10.1186/1758-2652-6-3-56 |
0.409 |
|
| 2004 |
van Leth F, Phanuphak P, Stroes E, Gazzard B, Cahn P, Raffi F, Wood R, Bloch M, Katlama C, Kastelein JJ, Schechter M, Murphy RL, Horban A, Hall DB, Lange JM, et al. Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naive patients infected with HIV-1. Plos Medicine. 1: e19. PMID 15526045 DOI: 10.1371/Journal.Pmed.0010019 |
0.388 |
|
| 2004 |
Baldwin CE, Sanders RW, Deng Y, Jurriaans S, Lange JM, Lu M, Berkhout B. Emergence of a drug-dependent human immunodeficiency virus type 1 variant during therapy with the T20 fusion inhibitor. Journal of Virology. 78: 12428-37. PMID 15507629 DOI: 10.1128/JVI.78.22.12428-12437.2004 |
0.339 |
|
| 2004 |
Sankatsing SU, Jurriaans S, van Swieten P, van Leth F, Cornelissen M, Miedema F, Lange JM, Schuitemaker H, Prins JM. Highly active antiretroviral therapy with or without mycophenolate mofetil in treatment-naive HIV-1 patients. Aids (London, England). 18: 1925-31. PMID 15353978 DOI: 10.1097/00002030-200409240-00008 |
0.448 |
|
| 2004 |
Lange JM, Perriens J, Kuritzkes D, Zewdie D. What policymakers should know about drug resistance and adherence in the context of scaling-up treatment of HIV infection. Aids (London, England). S69-74. PMID 15322488 DOI: 10.1097/00002030-200406003-00013 |
0.314 |
|
| 2004 |
Jurriaans S, Sankatsing SUC, Prins JM, Schuitemaker H, Lange J, Kuyl ACVD, Cornelissen M. HIV-1 seroreversion in an HIV-1-seropositive patient treated during acute infection with highly active antiretroviral therapy and mycophenolate mofetil. Aids. 18: 1607-1608. PMID 15238784 DOI: 10.1097/01.Aids.0000131367.05823.Ce |
0.578 |
|
| 2004 |
Gayle H, Lange JM. Seizing the opportunity to capitalise on the growing access to HIV treatment to expand HIV prevention. Lancet (London, England). 364: 6-8. PMID 15234835 DOI: 10.1016/S0140-6736(04)16607-5 |
0.497 |
|
| 2004 |
Nellen JF, Wit FW, De Wolf F, Jurriaans S, Lange JM, Prins JM. Virologic and immunologic response to highly active antiretroviral therapy in indigenous and nonindigenous HIV-1-infected patients in The Netherlands Journal of Acquired Immune Deficiency Syndromes. 36: 943-950. PMID 15220701 DOI: 10.1097/00126334-200408010-00008 |
0.44 |
|
| 2004 |
Cooper DA, Lange JM. Peptide inhibitors of virus-cell fusion: enfuvirtide as a case study in clinical discovery and development. The Lancet. Infectious Diseases. 4: 426-36. PMID 15219553 DOI: 10.1016/S1473-3099(04)01058-8 |
0.384 |
|
| 2004 |
Lowe SH, Sankatsing SU, Repping S, van der Veen F, Reiss P, Lange JM, Prins JM. Is the male genital tract really a sanctuary site for HIV? Arguments that it is not. Aids (London, England). 18: 1353-62. PMID 15199311 DOI: 10.1097/01.aids.0000125979.64033.96 |
0.408 |
|
| 2004 |
Law WP, Duncombe CJ, Mahanontharit A, Boyd MA, Ruxrungtham K, Lange JMA, Phanuphak P, Cooper DA, Dore GJ. Impact of viral hepatitis co-infection on response to antiretroviral therapy and HIV disease progression in the HIV-NAT cohort Aids. 18: 1169-1177. PMID 15166532 DOI: 10.1097/00002030-200405210-00010 |
0.501 |
|
| 2004 |
Blanckenberg DH, Wood R, Horban A, Beniowski M, Boron-Kaczmarska A, Trocha H, Halota W, Schmidt RE, Fatkenheuer G, Jessen H, Lange JM. Evaluation of nevirapine and/or hydroxyurea with nucleoside reverse transcriptase inhibitors in treatment-naive HIV-1-infected subjects. Aids (London, England). 18: 631-40. PMID 15090768 |
0.433 |
|
| 2004 |
Sankatsing SUC, Beijnen JH, Schinkel AH, Lange JMA, Prins JM. P glycoprotein in human immunodeficiency virus type 1 infection and therapy Antimicrobial Agents and Chemotherapy. 48: 1073-1081. PMID 15047504 DOI: 10.1128/Aac.48.4.1073-1081.2004 |
0.445 |
|
| 2004 |
van Sighem AI, van de Wiel MA, Ghani AC, Jambroes M, Reiss P, Gyssens IC, Brinkman K, Lange JM, de Wolf F. Mortality and progression to AIDS after starting highly active antiretroviral therapy. Aids (London, England). 17: 2227-36. PMID 14523280 DOI: 10.1097/00002030-200310170-00011 |
0.401 |
|
| 2003 |
Sankatsing SUC, Weverling GJ, Peeters M, Van't Klooster G, Gruzdev B, Rakhmanova A, Danner SA, Jurriaans S, Prins JM, Lange JMA. TMC125 exerts similar initial antiviral potency as a five-drug, triple class antiretroviral regimen Aids. 17: 2623-2627. PMID 14685056 DOI: 10.1097/00002030-200312050-00009 |
0.429 |
|
| 2003 |
Lange JM. Efficacy and durability of nevirapine in antiretroviral drug näive patients. Journal of Acquired Immune Deficiency Syndromes (1999). S40-52. PMID 14562857 DOI: 10.1097/00126334-200309011-00007 |
0.365 |
|
| 2003 |
Law WP, Dore GJ, Duncombe CJ, Mahanontharit A, Boyd MA, Ruxrungtham K, Lange JMA, Phanuphak P, Cooper DA. Risk of severe hepatotoxicity associated with antiretroviral therapy in the HIV-NAT Cohort, Thailand, 1996-2001 Aids. 17: 2191-2199. PMID 14523276 DOI: 10.1097/00002030-200310170-00007 |
0.306 |
|
| 2003 |
Sirivichayakul S, Ruxrungtham K, Ungsedhapand C, Techasathit W, Ubolyam S, Chuenyam T, Emery S, Cooper D, Lange J, Phanuphak P. Nucleoside analogue mutations and Q151M in HIV-1 subtype A/E infection treated with nucleoside reverse transcriptase inhibitors. Aids. 17: 1889-1896. PMID 12960821 DOI: 10.1097/00002030-200309050-00007 |
0.51 |
|
| 2003 |
Hazenberg MD, Otto SA, van Benthem BH, Roos MT, Coutinho RA, Lange JM, Hamann D, Prins M, Miedema F. Persistent immune activation in HIV-1 infection is associated with progression to AIDS. Aids (London, England). 17: 1881-8. PMID 12960820 DOI: 10.1097/00002030-200309050-00006 |
0.436 |
|
| 2003 |
Burger D, Hugen P, Reiss P, Gyssens I, Schneider M, Kroon F, Schreij G, Brinkman K, Richter C, Prins J, Aarnoutse R, Lange J. Therapeutic drug monitoring of nelfinavir and indinavir in treatment-naive HIV-1-infected individuals. Aids (London, England). 17: 1157-65. PMID 12819517 DOI: 10.1097/00002030-200305230-00007 |
0.331 |
|
| 2003 |
Lange JM, van Leeuwen R. Antiretroviral therapy and resistance to antiretroviral drugs. Ethiopian Medical Journal. 51-75. PMID 12802831 |
0.329 |
|
| 2003 |
Lazzarin A, Clotet B, Cooper D, Reynes J, Arastéh K, Nelson M, Katlama C, Stellbrink HJ, Delfraissy JF, Lange J, Huson L, DeMasi R, Wat C, Delehanty J, Drobnes C, et al. Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. The New England Journal of Medicine. 348: 2186-2195. PMID 12773645 DOI: 10.1056/Nejmoa035211 |
0.472 |
|
| 2003 |
Sankatsing SU, van Praag RM, van Rij RP, Rientsma R, Jurriaans S, Lange JM, Prins JM, Schuitemaker H. Dynamics of the pool of infected resting CD4 HLA-DR- T lymphocytes in patients who started a triple class five-drug antiretroviral regimen during primary HIV-1 infection. Antiviral Therapy. 8: 137-42. PMID 12741626 |
0.462 |
|
| 2003 |
Bogaards JA, Weverling GJ, Geskus RB, Miedema F, Lange JM, Bossuyt PM, Goudsmit J. Low versus high CD4 cell count as starting point for introduction of antiretroviral treatment in resource-poor settings: a scenario-based analysis. Antiviral Therapy. 8: 43-50. PMID 12713063 |
0.438 |
|
| 2003 |
Schwartländer B, Lange JM. Time to move on HIV/AIDS treatment and care. Iapac Monthly. 9: 6-7. PMID 12712942 |
0.411 |
|
| 2003 |
van Leeuwen R, Katlama C, Murphy RL, Squires K, Gatell J, Horban A, Clotet B, Staszewski S, van Eeden A, Clumeck N, Moroni M, Pavia AT, Schmidt RE, Gonzalez-Lahoz J, Montaner J, ... ... Lange JM, et al. A randomized trial to study first-line combination therapy with or without a protease inhibitor in HIV-1-infected patients. Aids (London, England). 17: 987-99. PMID 12700448 DOI: 10.1097/00002030-200305020-00007 |
0.524 |
|
| 2003 |
Burger D, Boyd M, Duncombe C, Felderhof M, Mahanontharit A, Ruxrungtham K, Ubolyam S, Stek M, Cooper D, Lange J, Phanupak P, Reiss P. Pharmacokinetics and pharmacodynamics of indinavir with or without low-dose ritonavir in HIV-infected Thai patients Journal of Antimicrobial Chemotherapy. 51: 1231-1238. PMID 12668574 DOI: 10.1093/Jac/Dkg198 |
0.4 |
|
| 2003 |
Koks CH, Huitema AD, Kroon ED, Chuenyam T, Sparidans RW, Lange JM, Beijnen JH. Population pharmacokinetics of itraconazole in Thai HIV-1-infected persons. Therapeutic Drug Monitoring. 25: 229-33. PMID 12657919 DOI: 10.1097/00007691-200304000-00014 |
0.337 |
|
| 2003 |
Geelen S, Lange J, Borleffs J, Wolfs T, Weersink A, Schuurman R. Failure to detect a non-B HIV-1 subtype by the HIV-1 Amplicor Monitor test, version 1.5: a case of unexpected vertical transmission. Aids (London, England). 17: 781-2. PMID 12646812 DOI: 10.1097/00002030-200303280-00027 |
0.445 |
|
| 2003 |
Cardiello PG, Monhaphol T, Mahanontharit A, van Heeswijk RP, Burger D, Hill A, Ruxrungtham K, Lange JM, Cooper DA, Phanuphak P. Pharmacokinetics of once-daily saquinavir hard-gelatin capsules and saquinavir soft-gelatin capsules boosted with ritonavir in HIV-1-infected subjects. Journal of Acquired Immune Deficiency Syndromes (1999). 32: 375-9. PMID 12640194 DOI: 10.1097/00126334-200304010-00005 |
0.359 |
|
| 2003 |
Boelaert JR, Dom GM, Huitema AD, Beijnen JH, Lange JM. The boosting of didanosine by allopurinol permits a halving of the didanosine dosage. Aids (London, England). 16: 2221-3. PMID 12409745 DOI: 10.1097/00002030-200211080-00016 |
0.467 |
|
| 2003 |
Ruxrungtham K, Ubolyam S, Hassink EA, Ungsedhapand C, Kroon E, Duncombe C, Weverling GJ, Nookai S, Lange J, Cooper D, Phanuphak P. Significant differences between plasma HIV-1 RNA assays in HIV-1 subtype E infected patients treated with antiretroviral therapy. Asian Pacific Journal of Allergy and Immunology. 20: 105-11. PMID 12403195 |
0.49 |
|
| 2003 |
Geelen S, Lange J, Borleffs J, Wolfs T, Weersink A, Schuurman R. Failure to detect a non-B HIV-1 subtype by the HIV-1 Amplicor Monitor test, version 1.5: a case of unexpected vertical transmission. Aids. 17: 781-782. DOI: 10.1097/01.Aids.0000060320.12269.66 |
0.532 |
|
| 2002 |
Hogg R, Cahn P, Katabira ET, Lange J, Samuel NM, O'Shaughnessy M, Vella S, Wainberg MA, Montaner J. Time to act: global apathy towards HIV/AIDS is a crime against humanity. Lancet (London, England). 360: 1710-1. PMID 12480418 DOI: 10.1016/S0140-6736(02)11722-3 |
0.509 |
|
| 2002 |
Wit FW, van Rij RP, Weverling GJ, Lange JM, Schuitemaker H. CC chemokine receptor 5 delta32 and CC chemokine receptor 2 64I polymorphisms do not influence the virologic and immunologic response to antiretroviral combination therapy in human immunodeficiency virus type 1-infected patients. The Journal of Infectious Diseases. 186: 1726-32. PMID 12447757 DOI: 10.1086/345677 |
0.339 |
|
| 2002 |
Sankatsing SUC, Droste J, Burger D, Van Praag RME, Jurriaans S, Lange JMA, Prins JM. Limited penetration of lopinavir into seminal plasma of HIV-1-infected men [5] Aids. 16: 1698-1700. PMID 12172099 DOI: 10.1097/00002030-200208160-00023 |
0.432 |
|
| 2002 |
van Heeswijk RP, Scherpbier HJ, de Koning LA, Heymans HS, Lange JM, Beijnen JH, Hoetelmans RM. The pharmacokinetics of nelfinavir in HIV-1-infected children. Therapeutic Drug Monitoring. 24: 487-91. PMID 12142631 DOI: 10.1097/00007691-200208000-00004 |
0.337 |
|
| 2002 |
Wit FW, Weverling GJ, Weel J, Jurriaans S, Lange JM. Incidence of and risk factors for severe hepatotoxicity associated with antiretroviral combination therapy. The Journal of Infectious Diseases. 186: 23-31. PMID 12089658 DOI: 10.1086/341084 |
0.321 |
|
| 2002 |
Ghani AC, Ferguson NM, Fraser C, Donnelly CA, Danner S, Reiss P, Lange J, Goudsmit J, Anderson RM, De Wolf F. Viral replication under combination antiretroviral therapy: a comparison of four different regimens. Journal of Acquired Immune Deficiency Syndromes (1999). 30: 167-76. PMID 12045679 DOI: 10.1097/00042560-200206010-00005 |
0.501 |
|
| 2002 |
van Rij RP, van Praag RM, Prins JM, Rientsma R, Jurriaans S, Lange JM, Schuitemaker H. Persistence of viral HLA-DR- CD4 T-cell reservoir during prolonged treatment of HIV-1 infection with a five-drug regimen. Antiviral Therapy. 7: 37-41. PMID 12008786 |
0.444 |
|
| 2002 |
Cardiello PG, van Heeswijk RP, Hassink EA, Srasuebkul P, Mahanontharit A, Samor TM, Worarien W, Beijnen JH, Hoetelmans RM, Ruxrungtham K, Cooper DA, Lange JM, Phanuphak P. Simplifying protease inhibitor therapy with once-daily dosing of saquinavir soft-gelatin capsules/ritonavir (1600/100 mg): HIVNAT 001.3 study. Journal of Acquired Immune Deficiency Syndromes (1999). 29: 464-70. PMID 11981362 DOI: 10.1097/00042560-200204150-00006 |
0.42 |
|
| 2002 |
Goudsmit J, Bogaards JA, Jurriaans S, Schuitemaker H, Lange JM, Coutinho RA, Weverling GJ. Naturally HIV-1 seroconverters with lowest viral load have best prognosis, but in time lose control of viraemia. Aids (London, England). 16: 791-3. PMID 11964537 DOI: 10.1097/00002030-200203290-00016 |
0.615 |
|
| 2002 |
van Praag RM, Wit FW, Jurriaans S, de Wolf F, Prins JM, Lange JM. Improved long-term suppression of HIV-1 replication with a triple-class multidrug regimen compared with standard of care antiretroviral therapy. Aids (London, England). 16: 719-25. PMID 11964528 DOI: 10.1097/00002030-200203290-00007 |
0.429 |
|
| 2002 |
Kostense S, Otto SA, Knol GJ, Manting EH, Nanlohy NM, Jansen C, Lange JM, van Oers MH, Miedema F, van Baarle D. Functional restoration of human immunodeficiency virus and Epstein-Barr virus-specific CD8(+) T cells during highly active antiretroviral therapy is associated with an increase in CD4(+) T cells. European Journal of Immunology. 32: 1080-9. PMID 11920575 DOI: 10.1002/1521-4141(200204)32:4<1080::AID-IMMU1080>3.0.CO;2-R |
0.339 |
|
| 2002 |
van Rij RP, Visser JA, van Praag RM, Rientsma R, Prins JM, Lange JM, Schuitemaker H. Both R5 and X4 human immunodeficiency virus type 1 variants persist during prolonged therapy with five antiretroviral drugs. Journal of Virology. 76: 3054-8. PMID 11861873 DOI: 10.1128/jvi.76.6.3054-3058.2002 |
0.411 |
|
| 2001 |
Ruiz L, Negredo E, Domingo P, Paredes R, Francia E, Balagué M, Gel S, Bonjoch A, Fumaz CR, Johnston S, Romeu J, Lange J, Clotet B. Antiretroviral treatment simplification with nevirapine in protease inhibitor-experienced patients with hiv-associated lipodystrophy: 1-year prospective follow-up of a multicenter, randomized, controlled study. Journal of Acquired Immune Deficiency Syndromes. 27: 229-236. PMID 11464141 DOI: 10.1097/00126334-200107010-00003 |
0.538 |
|
| 1999 |
Hirsch M, Steigbigel R, Staszewski S, Mellors J, Scerpella E, Hirschel B, Lange J, Squires K, Rawlins S, Meibohm A, Leavitt R. A randomized, controlled trial of indinavir, zidovudine, and lamivudine in adults with advanced human immunodeficiency virus type 1 infection and prior antiretroviral therapy. The Journal of Infectious Diseases. 180: 659-65. PMID 10438352 DOI: 10.1086/314948 |
0.515 |
|
| 1998 |
Raboud JM, Montaner JS, Conway B, Rae S, Reiss P, Vella S, Cooper D, Lange J, Harris M, Wainberg MA, Robinson P, Myers M, Hall D. Suppression of plasma viral load below 20 copies/ml is required to achieve a long-term response to therapy. Aids (London, England). 12: 1619-24. PMID 9764780 DOI: 10.1097/00002030-199813000-00008 |
0.408 |
|
| 1998 |
Hall DB, Montaner JGS, Reiss P, Cooper D, Vella S, Dohnanyi C, Myers M, Lange J, Conway B. Induction-maintenance antiretroviral therapy: proof of concept. Aids. 12. PMID 9619796 DOI: 10.1097/00002030-199807000-00001 |
0.36 |
|
| 1998 |
Lange J. Session A: Natural history of HIV disease and predictors of clinical outcome. Journal of Acquired Immune Deficiency Syndromes. 17. PMID 9586652 DOI: 10.1097/00042560-199801001-00013 |
0.48 |
|
| 1998 |
Renwick N, Halaby T, Weverling GJ, Valk M, Hemmelder B, Kempen Iv, Simpson G, Schulz T, Lange J, Goudsmit J. Hhv8 Antibody Seropositivity Is Predictive Of Ks Development In Hiv-1 Infected Individuals. Journal of Acquired Immune Deficiency Syndromes. 17. DOI: 10.1097/00042560-199804010-00071 |
0.645 |
|
| 1995 |
Lange J. Combination Antiretroviral Therapy Back to the Future Drugs. 49: 32-37. PMID 7614900 DOI: 10.2165/00003495-199500491-00008 |
0.512 |
|
| 1992 |
Lange JM, van der Noordaa J. [Development in and role of antiviral agents]. Nederlands Tijdschrift Voor Geneeskunde. 136: 958-64. PMID 1317510 |
0.479 |
|
| 1990 |
Mulder JW, de Wolf F, Goudsmit J, Cload PA, Coutinho RA, Fiddian AP, Schellekens PT, van der Noordaa J, Lange JM. Long-term zidovudine treatment of asymptomatic HIV-1-infected subjects. Antiviral Research. 13: 127-38. PMID 1972321 DOI: 10.1016/0166-3542(90)90028-6 |
0.732 |
|
| 1989 |
de Wolf F, Lange JM, Houweling JT, Mulder JW, Beemster J, Schellekens PT, Coutinho RA, van der Noordaa J, Goudsmit J. Appearance of predictors of disease progression in relation to the development of AIDS. Aids (London, England). 3: 563-9. PMID 2571348 DOI: 10.1097/00002030-198909000-00002 |
0.759 |
|
| 1989 |
Lange JM, de Wolf F, Mulder JW, Coutinho RA, van der Noordaa J, Goudsmit J. Markers for progression to acquired immune deficiency syndrome and zidovudine treatment of asymptomatic patients. The Journal of Infection. 18: 85-91. PMID 2492586 DOI: 10.1016/S0163-4453(89)80087-8 |
0.759 |
|
| 1988 |
Lange JM, Goudsmit J, De Wolf F, Coutinho RA, van der Noordaa J. Serological markers in HIV infection. Annales De Mã©Decine Interne. 139: 80-3. PMID 3293504 |
0.763 |
|
| 1988 |
de Wolf F, Lange JM, Houweling JT, Coutinho RA, Schellekens PT, van der Noordaa J, Goudsmit J. Numbers of CD4+ cells and the levels of core antigens of and antibodies to the human immunodeficiency virus as predictors of AIDS among seropositive homosexual men. The Journal of Infectious Diseases. 158: 615-22. PMID 3261763 DOI: 10.1093/Infdis/158.3.615 |
0.657 |
|
| 1988 |
de Wolf F, Lange JM, Bakker M, Tjong-A-Hung S, Hooykaas C, Coutinho R, van der Noordaa J, Goudsmit J. Influenza-like syndrome in homosexual men: a prospective diagnostic study. The Journal of the Royal College of General Practitioners. 38: 443-5. PMID 3256668 |
0.745 |
|
| 1988 |
De Wolf F, Roos M, Lange JM, Houweling JT, Coutinho RA, van der Noordaa J, Schellekens PT, Goudsmit J. Decline in CD4+ cell numbers reflects increase in HIV-1 replication. Aids Research and Human Retroviruses. 4: 433-40. PMID 2905892 DOI: 10.1089/Aid.1988.4.433 |
0.762 |
|
| 1988 |
Epstein LG, Boucher CA, Morrison SH, Connor EM, Oleske JM, Lange JM, van der Noordaa J, Bakker M, Dekker J, Scherpbier H. Persistent human immunodeficiency virus type 1 antigenemia in children correlates with disease progression. Pediatrics. 82: 919-24. PMID 2903481 |
0.712 |
|
| 1988 |
de Wolf F, Lange JM, Goudsmit J, Cload P, de Gans J, Schellekens PT, Coutinho RA, Fiddian AP, van der Noordaa J. Effect of zidovudine on serum human immunodeficiency virus antigen levels in symptom-free subjects. Lancet. 1: 373-6. PMID 2893187 DOI: 10.1016/S0140-6736(88)91179-8 |
0.714 |
|
| 1987 |
de Wolf F, Goudsmit J, Paul DA, Lange JM, Hooijkaas C, Schellekens P, Coutinho RA, van der Noordaa J. Risk of AIDS related complex and AIDS in homosexual men with persistent HIV antigenaemia. British Medical Journal (Clinical Research Ed.). 295: 569-72. PMID 3117235 DOI: 10.1136/Bmj.295.6598.569 |
0.76 |
|
| 1987 |
Lange J, Goudsmit J. Decline of antibody reactivity to HIV core protein secondary to increased production of HIV antigen. The Lancet. 329: 448-448. PMID 2880240 DOI: 10.1016/S0140-6736(87)90148-6 |
0.669 |
|
| 1986 |
Lange JM, Paul DA, Huisman HG, de Wolf F, van den Berg H, Coutinho RA, Danner SA, van der Noordaa J, Goudsmit J. Persistent HIV antigenaemia and decline of HIV core antibodies associated with transition to AIDS. British Medical Journal (Clinical Research Ed.). 293: 1459-62. PMID 3099912 DOI: 10.1136/Bmj.293.6560.1459 |
0.764 |
|
| 1986 |
Lange JM, Coutinho RA, Krone WJ, Verdonck LF, Danner SA, van der Noordaa J, Goudsmit J. Distinct IgG recognition patterns during progression of subclinical and clinical infection with lymphadenopathy associated virus/human T lymphotropic virus. British Medical Journal (Clinical Research Ed.). 292: 228-30. PMID 3004634 DOI: 10.1136/Bmj.292.6515.228 |
0.631 |
|
| 1986 |
Goudsmit J, de Wolf F, Paul DA, Epstein LG, Lange JM, Krone WJ, Speelman H, Wolters EC, Van der Noordaa J, Oleske JM. Expression of human immunodeficiency virus antigen (HIV-Ag) in serum and cerebrospinal fluid during acute and chronic infection. Lancet. 2: 177-80. PMID 2873436 DOI: 10.1016/S0140-6736(86)92485-2 |
0.751 |
|
| Show low-probability matches. |
